


eISBN: 978-1-60805-930-0
ISBN: 978-1-60805-931-7

eISSN: 2542-9175
ISSN: 2542-9167

Frontiers in Pain Science

Volume 1

New Non-opioid Analgesics: Understanding Molecular Mechanisms on the Basis of Patch-clamp and Quantum-chemical Studies



**Boris V. Krylov
Ilya V. Rogachevskii
Tatiana N. Shelykh
Vera B. Plakhova**

Bentham  Books

Frontiers in Pain Science

(Volume 1)

*(New Non-opioid Analgesics: Understanding Molecular
Mechanisms on the Basis of Patch-clamp and
S wcpwo /chemical Studies)*

Authored by:

**Boris V. Krylov, Ilia V. Rogachevskii, Tatiana
N. Shelykh & Vera B. Plakhova**

*I.P. Pavlov Institute of Physiology Russian Academy of Sciences,
St. Petersburg, Russia*

Frontiers in Pain Science

Volume # 1

New Non-opioid Analgesics: Understanding Molecular Mechanisms on the Basis of Patch-clamp and Quantum-chemical Studies

Author: Boris V. Krylov, Ilia V. Rogachevskii, Tatiana N. Shelykh & Vera B. Plakhova

eISSN (Online): 2542-9175

ISSN (Print): 2542-9167

eISBN (Online): 978-1-60805-930-0

ISBN (Print): 978-1-60805-931-7

©2017, Bentham eBooks imprint

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

First published in 2017.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
 - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
 - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided “as is” without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: subscriptions@benthamscience.org



CONTENTS

PREFACE	i
CHAPTER 1 INTRODUCTION AND METHODOLOGY	3
PHYSIOLOGY OF PRIMARY SENSORY CODING	3
ROLE OF ION CHANNELS IN PRIMARY SENSORY CODING	9
Selectivity Filter	12
Inactivation Gating Device	14
Activation Gating Device	15
LIMITING SLOPE PROCEDURE	15
Mathematical Modeling of Z_{eff} Evaluation by the Limiting Logarithmic Voltage Sensitivity Method	18
<i>m-model</i>	19
<i>m³-model</i>	20
<i>m³h_s-model</i>	21
<i>m³h_f-model</i>	23
PROBABLE ROLE OF EFFECTIVE CHARGE TRANSFER IN NOCICEPTIVE INFORMATION CODING	28
PATCH-CLAMP RESULTS OF Z_{EFF} EVALUATION BY THE LIMITING LOGARITHMIC VOLTAGE SENSITIVITY METHOD	39
CONCLUSION	46
CONFLICT OF INTEREST	47
ACKNOWLEDGEMENTS	47
REFERENCES	47
CHAPTER 2 POSSIBLE MECHANISMS OF BINDING OF GAMMA-PYRONES TO THE OPIOID-LIKE RECEPTOR	62
PATCH-CLAMP INVESTIGATION OF GAMMA-PYRONES	63
QUANTUM-CHEMICAL STUDY OF GAMMA-PYRONES	68
Free Acids	73
Acid Anions	75
Sodium and Calcium Salts	77
Complexes with Ca^{2+}	81
Sodium and Calcium Salts of Ca^{2+} Complexes	84
Energy Effects of Salt Formation and Ca^{2+} Chelation	88
CONCLUSION	90
CONFLICT OF INTEREST	92
ACKNOWLEDGEMENTS	92
REFERENCES	92
CHAPTER 3 POSSIBLE MECHANISMS OF BINDING OF GAMMA-PYRIDONES TO THE OPIOID-LIKE RECEPTOR	96
PATCH-CLAMP INVESTIGATION OF GAMMA-PYRIDONES	97
QUANTUM-CHEMICAL STUDY OF GAMMA-PYRIDONES	104
Free Acids	107
Complexes with Ca^{2+}	110
Acid Anions	113
Calcium Salts	115
Calcium Salts of Ca^{2+} Complexes	117
Energy Effects of Salt Formation and Ca^{2+} Chelation	119
Structure of Molecule F (5-hydroxy-2-hydroxymethyl-gamma-pyridone)	120
CONCLUSION	122
CONFLICT OF INTEREST	123
ACKNOWLEDGEMENTS	123
REFERENCES	123

CHAPTER 4 POSSIBLE MECHANISMS OF LIGAND-RECEPTOR BINDING	
QUANTUM-CHEMICAL STUDY OF CARDIOTONIC STEROIDS	127
PATCH-CLAMP INVESTIGATION OF CARDIOTONIC STEROIDS	128
QUANTUM-CHEMICAL STUDY OF CARDIOTONIC STEROIDS	138
Ouabain and Ouabagenin	138
Ouabain–Ca ²⁺ Chelate Complexes	149
Ouabagenin–Ca ²⁺ Chelate Complexes	160
Marinobufagenin	170
CONCLUSION	177
CONFLICT OF INTEREST	178
ACKNOWLEDGEMENTS	178
REFERENCES	178
CHAPTER 5 CONCLUDING REMARKS	183
OPIOID-LIKE RECEPTOR-COUPLED MECHANISM OF Na_v1.8 CHANNELS MODULATION	184
TRANSDUCER-COUPLED MECHANISM OF Na_v1.8 CHANNELS MODULATION	186
MODULATED RECEPTOR MECHANISM OF Na_v1.8 CHANNELS CONTROL	188
CONFLICT OF INTEREST	189
ACKNOWLEDGEMENTS	189
GLOSSARY	190
REFERENCES	193
SUBJECT INDEX	195

PREFACE

In 1897, at a meeting of the Society of Russian Physicians, Ivan Pavlov predicted that the last stage of the life sciences would be the physiology of the living molecule. Nowadays the last stages of molecular approaches are theoretical quantum-chemical calculational techniques and experimental patch-clamp method which really can describe the behavior of living molecules. An attempt of combined application of quantum-chemical calculations and the patch-clamp method to investigation of the nociceptive system is presented in this volume. The crosstalk between drug substances and membrane receptors is conducted in the language of molecules. The behavior of single molecules upon their ligand-receptor binding should be investigated at physiologically adequate conditions during development of new analgesics. The requirement of physiological adequacy was always taken into account when the authors tried to explain the background mechanisms governing the effects of powerful analgesics. This approach makes it possible to elucidate how the chemical structure of labile attacking molecules should be finely tuned to provide effective binding to their membrane receptor. The authors hope that this review will open a new perspective to application of molecular methods in the drug design of pain relievers. The urgent need for the development of novel analgesics is dictated by the lack of safe and effective drugs in this field of medicine, especially when the pain becomes intolerable and incurable. The arsenal of practical medicine includes an array of analgesics, which have to be applied basing on the severity of pathological conditions of the organism. Step 1 of the World Health Organization analgesic ladder consists of non-opioids, administered with or without adjuvants depending on the type of pain. Step 2 comprises step 1 agents plus opioids which can relieve mild to moderate pain. Step 3 involves step 2 agents with addition of opioids for moderate to severe pain relief. It is a matter of common knowledge that administration of opioid substances results in irreversible adverse side effects in humans. The major objective of the authors is to solve this underlying problem by creating novel analgesics which could replace opioids in clinical practice, while remaining completely safe.

This book presents our main result in elucidation of the physiological role of a novel membrane signaling pathway involving the opioid-like receptor coupled to slow sodium channels ($\text{Na}_v1.8$) via Na^+, K^+ -ATPase as the signal transducer. This pathway is distinct from and additional to the known mechanism of the opioidergic system functioning that involves G proteins. Activation of the opioid-like receptor further triggering the signaling pathway directed towards $\text{Na}_v1.8$ channels provides the effectiveness and safety of our novel analgesic which is potent enough to relieve severe pain otherwise relieved exclusively by Step 3 opioids.

It is nowadays almost inevitable for reviewers of scientific material in the field of nociception to make excuses for omissions. We are sincerely sorry for not having been able to discuss all the findings in physiology of nociception and in practical medicine that would have merited attention. To include all would have defeated the purpose of this volume by making it grow out of all proportions.

This book presents an informative and valuable for physiologists and clinicians overview of primary molecular mechanisms involved in functioning of the peripheral nociceptive system. This material can be used in courses given to students specializing in physiology, psychology, and medicine, as well as to physicians training in neurology, neurosurgery, and psychiatry. The principles presented in the current volume may also be of interest to molecular biologists engaged in the drug design.

Boris V. Krylov

Ilia V. Rogachevskii

Tatiana N. Shelykh

Vera B. Plakhova

I.P. Pavlov Institute of Physiology
Russian Academy of Sciences
St. Petersburg,
Russia

Introduction and Methodology

Abstract: Discovery of $\text{Na}_v1.8$ channels has opened a new perspective to study the mechanisms of nociception. A remarkable feature of these channels is their ability to be modulated by binding of various endogenous and exogenous agents to membrane receptors coupled to $\text{Na}_v1.8$ channels. The behavior of their activation gating system was patch-clamp recorded and analyzed by the Almers' limiting slope method. It was established that opioid-like membrane receptors could control the functioning of $\text{Na}_v1.8$ channels. A novel role in this mechanism is played by Na^+, K^+ -ATPase, which serves as the signal transducer instead of G proteins. Switching on the opioid-like receptors one can selectively decrease the effective charge of $\text{Na}_v1.8$ channel activation gating device. As a result, only the high-frequency component of nociceptive membrane impulse firing is inhibited. This is the component that transfers nociceptive information to CNS.

The three units involved in the described membrane signaling cascade (opioid-like receptor \rightarrow Na^+, K^+ -ATPase \rightarrow $\text{Na}_v1.8$ channel) are potential targets for novel analgesics. Investigation of this mechanism of nociceptive signal modulation is of major importance not only for fundamental physiology but also for clinical medicine.

Keywords: Impulse firing, Limiting slope procedure, $\text{Na}_v1.8$ channels, Na^+, K^+ -ATPase, Nociception, Opioid-like receptor, Patch-clamp method.

PHYSIOLOGY OF PRIMARY SENSORY CODING

The universal language of the brain is the language of nerve impulses. In the 1920s Edgar Adrian was the first who discovered that discharge frequency of an afferent fiber innervating feline mechanoreceptors increased as a consequence of an increase in the stimulus intensity. The input-output function of the primary afferent fiber describes the relationship between the stimulus intensity and the number and frequency of evoked action potentials [1]. Different forms of energy are transformed by the nervous system into different sensations of sensory modalities. Five major sensory modalities have been recognized since ancient times: vision, hearing, touch, taste, and smell. In 1844 Johannes Müller advanced his "laws of specific sense energies" [2]. He proposed that modality was a property of the sensory nerve fiber. Each fiber is activated by a certain type of stimulus because different stimuli activate different nerve fibers. In turn, the nerve

fibers make specific connections within the nervous system, and it is these specific connections that are responsible for specific sensations. A unique stimulus that activates a specific receptor and therefore a particular nerve fiber was called an adequate stimulus by Charles Sherrington [3]. In 1967 Vernon Mountcastle advanced the idea of the brain as a “linear operator” [4, 5]. It means that the input-output functions of sense organs should be congruent with psychophysical functions relating the magnitude of the stimulus to the sensation. For instance, the function of central pathways mediating simple sensory events in the somatosensory system is thought to conserve the presentation of a stimulus dictated by the peripheral sensory apparatus. Said differently, one could assign for each discriminable quality of sensation a specific set of nerve fibers whose excitation would express that one quality (modality) and no other. The alternative view stated that quality was a matter of the pattern or of the spatio-temporal distribution of excitation in a whole array of fibers. As a result, the “labeled line” theory was opposed to the alternative “pattern” theory (see review) [6].

The “sixth” sensory modality, *i.e.* pain, up to now attracts special attention of physiologists and clinicians. It is difficult to overestimate the significance of attempts to control the mechanisms of pain sensation in order to achieve practical results regarding chronic pain relief in humans. The first steps in this direction have been done by researchers who laid the foundations of nociception as one of the most important branches of sensory physiology.

Alfred Goldscheider (1920) [7] was the first to advance the idea that the pain was not modality-specific but rather evoked by an additional excitation of any sense organ.

Ivan Pavlov (1927) [8] showed how the brain could be trained, through repetition, to invoke certain reactions in certain circumstances. Pavlov distinguished between food stimulations which called out the reaction of salivation and electric current noxious stimulations which called out the defense reaction. Destructive (noxious) stimuli provoke the defense reflex. Food calls for a positive reaction – grasping of the substance and eating it. Pavlov has shown that the defense reflex of skin is second in importance to the food reflex. An animal exposed simultaneously to an electric current acting upon his skin and to a food stimulus would respond not with defense but with food reaction. These findings show that mediation of nociceptive signals does not strictly obey the “labeled line” law. This “line” is under control of some other physiological processes of living organism.

Investigating the physiological nature of sleep Pavlov stated that sleep, or inhibition, prevented undue fatigue of the cortical elements, allowing them, after they had been subjected to noxious stimulation, to recover their normal state.

Inhibition is occurring all the time, even in a seemingly alert animal, but it exists only in scattered areas of the cortex. When it irradiates from these areas over the entire brain, the animal falls asleep. In Pavlov's words, "internal inhibition in the alert state of the animal represents a regional distribution of sleep which is kept within bounds by antagonistic nervous process of excitation" (Pavlov, *Conditioned reflexes*, p. 253) [8]. Pavlov has demonstrated that the nature of the stimulus itself is less important than the inhibition associated with it. "As there is practically no stimulus of whatever strength that cannot, under certain conditions, become subjected to internal inhibition, so also there is none which cannot produce sleep" (Pavlov, *Conditioned reflexes*, p.252) [8]. He mentions an instance in which a powerful electric shock applied to the skin was used as a conditioned alimentary stimulus that totally relieved pain (see also [9]).

There are three main consequences of Pavlov's findings. The first one is that his results corroborate the "pattern" theory, because as it was mentioned above, the "noxious labeled line" could be easily disrupted by signals of other modalities in an alert organism. The second consequence is the suggestion that nociceptive signals can be controlled somewhere at spinal and/or supraspinal levels. And finally, nowadays we can predict that endogenous substances which should control pain sensation on the molecular level are expressed in human brain.

A starting point of any sensation is the reception of signals evoked by activation of specialized sensory receptors (including nociceptors) providing information to CNS. Nociceptors inform us mainly about harmful external and internal stimuli or about tissue injury. Pain is the perception of an aversive or unpleasant sensation that originates from a damaged region of the body. Our "sixth sense" is a vitally important sensory experience that warns us on danger. Modern findings concerning the relationship between perception of pain and mechanisms of functioning of nociceptors show that any nociceptive perception involves an interconnection and elaboration of sensory inputs and pathways. Highly subjective and complicated nature of pain makes it difficult to diagnose and treat a number of chronic pain phenomena.

A noxious stimulus activates the nociceptor fiber by the fundamental mechanism of excitation of living cell. It is well known that nerve excitation evoked by mechanical stimulation results in production of gradual receptor current in primary receptors [10, 11] or generator current in secondary receptors [12] that elicits the single action potential or trains of nerve impulses. Insights into neural mechanisms for fine coding of tactile information in humans come from the works of Ake Vallbo and his colleagues who have systematically studied mechanoreceptors innervating the human hand skin. On the basis of information obtained on alert subjects they have proven that even single extra action potential

Possible Mechanisms of Binding of Gamma-Pyrones to the Opioid-Like Receptor

Abstract: Derivatives of gamma-pyrone show their remarkable ability to trigger the novel mechanism of $\text{Na}_v1.8$ channels modulation described in Chapter 1. Unlike morphine, which activates both opioid and opioid-like receptors, comenic acid specifically switches on the latter mechanism involving Na^+, K^+ -ATPase as the signal transducer. It is extremely important that not any gamma-pyrone derivative can decrease the voltage sensitivity of $\text{Na}_v1.8$ channels, though all molecules studied herein share a rather similar chemical structure. A very productive approach which makes it possible to elucidate the peculiarities of ligand-receptor binding on the molecular level is combined application of quantum-chemical calculations and the patch-clamp method. Below we present our findings that explain a totally unevident result of highly selective binding of gamma-pyrone derivatives to the opioid-like receptor. Understanding of this mechanism opens up opportunities for creation of a novel class of analgesics.

Keywords: Ca^{2+} chelate complex, Gamma-pyrone derivatives, Limiting slope procedure, $\text{Na}_v1.8$ channels, Nociception, Opioid-like receptor, Patch-clamp method, Quantum-chemical calculations.

Pharmacological effects of gamma-pyrone derivatives, including radioprotective [1 - 3], antiviral [4], antidiabetic [5], and anticonvulsant [6] effects, were recently examined. Kojic acid was demonstrated to be able to protect human skin from pigmentation [7, 8]. Gamma-pyrones are regarded as potential anticancer drugs [9]. They also exhibit antileishmanial activity [10].

Kojic acid derivatives were found to effectively modulate histamine H3 receptors (H3R). The most affine compounds showed receptor binding in the low nanomolar concentration range [11]. The authors suggest that antagonists/inverse agonists of the H3R are able to increase the neurotransmitter content and may find their application in the therapy of cognitive diseases, sleep/wake disorders, epilepsy, obesity, pain, or allergic rhinitis. Several substances are progressing in clinical trials [11].

Fundamentally new opportunities for clinical use of gamma-pyrone were discovered by Alexey Shurygin who developed food additive Baliz-2 [12, 13]. Its main ingredients, comenic and meconic acids, exhibit a profound antibiotic, antibacterial, and regenerative activity. It is worth noting that Baliz-2 never expressed any negative side effects during its long history of clinical application in Russia. Our starting investigations of probable molecular mechanisms of meconic and comenic acid targeting were inspiring: the agents decreased voltage sensitivity of $\text{Na}_v1.8$ channels [14]. These findings opened a promising perspective for research of the role of gamma-pyrone derivatives in nociception (see also [15]).

PATCH-CLAMP INVESTIGATION OF GAMMA-PYRONES

The families of $\text{Na}_v1.8$ currents in the control experiment and after extracellular application of comenic acid (5-hydroxy-gamma-pyrone-2-carboxylic acid, substance A) are presented in Fig. (2.1.a). It is clearly seen that the amplitude values of the currents are decreased, which can find its partial explanation in the existence of “run-down” effect inherent to the patch-clamp method [16, 17]. However, the decrease of the channels density may also take place. The peak current-voltage curve shifts in the depolarizing direction after comenic acid has been applied (Fig. 2.1.b). The left branch of the current-voltage function is steeper as a result of comenic acid application than in the control experiments. The voltage dependencies of normalized $G_{\text{Na}_s}(E)$ functions also differ between the control and comenic acid data at negative E (Fig. 2.2.a). When $G_{\text{Na}_s}(E)$ dependencies are obtained, the Almers' limiting slope procedure can be applied, making it possible to evaluate Z_{eff} at the most negative potentials E (Fig. 2.2.b). A very pronounced decrease in Z_{eff} after extracellular application of comenic acid occurs due to activation of the receptor-coupled membrane mechanism (Fig. 1.17). Indeed, a nonspecific opioid antagonist naltrexone (NTX) switched off the effect of comenic acid (Fig. 2.3). Z_{eff} also remained fairly unchanged after combined application of comenic acid and a specific blocker of Na^+, K^+ -ATPase, ouabain, at 200 μM (Fig. 2.3). Ouabain applied at this rather high concentration totally inhibits Na^+, K^+ -ATPase, therefore interrupting transduction of the signal triggered by binding of comenic acid to the opioid-like receptor and sent to $\text{Na}_v1.8$ channels according to the mechanism proposed earlier [18]. Moreover, these findings indicate that comenic acid can be compared to morphine in its efficiency of $\text{Na}_v1.8$ channel modulation. It switches on the three background mechanisms: reduces the channels density, positively shifts $\text{Na}_v1.8$ channel activation gating process, and, most importantly, markedly decreases Z_{eff} . The latter process is of dose-dependent nature, showing opioid-like receptor binding in the nanomolar concentration range. The binding process is characterized by $K_d = 100$ nM and the Hill coefficient $n = 0.5$ [14].




Fig. (2.1). Effects of comenic acid on Na_v1.8 channels.

a – Families of sodium currents measured in the control experiment (top) and after application of comenic acid at 100 nM (bottom);

b – Positive shift of the normalized peak current-voltage curve after application of comenic acid.

Possible Mechanisms of Binding of Gamma-Pyridones to the Opioid-Like Receptor

Abstract: The nociceptive system codes noxious signals by increasing its impulse firing. Na_v1.8 channels play a central role in the process of primary sensory coding. The Almers' method is almost ideal for the study of behavior of their gating device. Application of this method makes it possible to elucidate the mechanism of receptor-coupled modulation of Na_v1.8 channels by opioid-like receptors, which exhibit high affinity to some gamma-pyrone and gamma-pyridone derivatives. A remarkable feature characterizing these substances is their ability to chelate calcium. That is why opioid-like receptors recognize these attacking molecules in physiologically appropriate conditions by activation of a very important additional mechanism of ion-ionic interactions switched on by attacking molecules with chelated calcium. This conclusion is confirmed by the study of the effects of gamma-pyridone derivatives, which are structurally very close to gamma-pyrones and, in addition, also have an ability to chelate calcium.

The results discussed in this and the previous chapters open a new approach to solve the problem of recognition of medicinal analgesic substances. Our quantum-chemical calculations demonstrate that calcium chelation process plays an important role in ligand-receptor binding and it is energetically allowed not only in vacuum but also in the adequate physiological environment. Conclusions concerning the probable structure of opioid-like receptor binding pocket are presented.

Keywords: Ca²⁺ chelate complex, Gamma-pyridone derivatives, Limiting slope procedure, Na_v1.8 channels, Nociception, Opioid-like receptor, Patch-clamp method, Quantum-chemical calculations.

The main result obtained in Chapter 2 of this book is elucidation of the physiological role of calcium chelation by gamma-pyrone derivatives, which is fundamentally important for ligand-receptor binding. Participation of the calcium ion in binding of gamma-pyrones to the opioid-like receptor is completely not obvious, and it allows introducing a new approach to analyze physiological activity of potential analgesics. This conclusion can be additionally verified by investigation of physiological effects of molecules relating to a class of substances, similar in structure to gamma-pyrones. We have chosen for our

further studies gamma-pyridone derivatives, which are distinguished from gamma-pyrones by the nature of the ring heteroatom (gamma-pyridones contain a nitrogen atom, as opposed to an oxygen atom in gamma-pyrones).

Many gamma-pyridones are demonstrated to be of pharmacological importance: they can exhibit analgesic activity [1 - 5], display anti-inflammatory [3, 4, 6], antitumor [7, 8], antibacterial [9, 10], antimicrobial [11], antimalarial effects [12], positively influence the cardiovascular system [13] and can also be applied for the treatment of Parkinson's disease [14].

3-Hydroxy-gamma-pyridone derivatives are widely used in various fields of medicinal chemistry to treat the diseases caused by excess microelements in serum [15 - 17], as well as to design radioactive and fluorescent labels for diagnostics [17]. These applications of 3-hydroxy-gamma-pyridones are based on their ability to chelate doubly and triply charged cations (Al^{3+} , Fe^{3+} , Ga^{3+} , Zn^{2+} , Cu^{2+} , Ca^{2+} , Mg^{2+}) [17 - 20] through the carbonyl and hydroxyl groups at contiguous positions of the pyridone ring.

PATCH-CLAMP INVESTIGATION OF GAMMA-PYRIDONES

Insofar as gamma-pyridones are structurally related to gamma-pyrones discussed in Chapter 2, it is of interest to investigate the effect of the ring heteroatom on physiological and structural properties of these compounds in order to find a new mechanism or new agents capable of acting as analgesics by selective modulation of $Na_v1.8$ channels. Two molecules were chosen to examine their ability to decrease the effective charge of $Na_v1.8$ channel activation gating device: 5-hydroxy-1-methyl-gamma-pyridone-2-carboxylic acid (substance E) and 5-hydroxy-2-hydroxymethyl-gamma-pyridone (substance F). Their structural formulae are presented in Fig. (3.1). It is important that the latter compound is a structural analog of kojic acid (substance D, Fig. 2.8) which showed no appreciable activity in our patch-clamp experiments, while the former one is a structural analog of comenic acid (substance A, Fig. 2.8) which is capable to activate the opioid-like receptor being applied at nanomolar concentrations.

The families of $Na_v1.8$ currents in the control experiment and after extracellular application of substance E are presented in Fig. (3.2.a). It is clearly seen that the amplitude values of the currents are reduced, indicating that the decrease of the channels density may take place. The peak current-voltage curve shifts in the depolarizing direction after substance E has been applied (Fig. 3.2.b). The voltage dependencies of normalized $G_{Na_s}(E)$ functions differ between the control and substance E data at negative potentials. In the latter case this function is steeper (Fig. 3.3.a). When $G_{Na_s}(E)$ dependencies are obtained, the Almers' limiting slope procedure can be applied, making it possible to evaluate Z_{eff} at the most negative

potentials (Fig. 3.3.b). Our experimental results demonstrate that substance F is also able to decrease Z_{eff} of $\text{Na}_v1.8$ channel activation gating system. Its action is characterized by only two manifestations of inhibitory properties: it reduces the amplitude values of the currents (Fig. 3.4.a) and decreases Z_{eff} (Fig. 3.5). Somewhat unexpected in this case is the lack of the voltage shift of $\text{Na}_v1.8$ channels activation gating process (Fig. 3.4.b). On the contrary, the effects of substance E are absolutely of the same character as those observed after morphine or comenic acid application (Figs. 1.13, 2.2). The decrease in Z_{eff} after extracellular application of substance E occurs due to activation of the receptor-coupled membrane mechanism (Fig. 1.17). Indeed, this conclusion is based on the fact that nonspecific opioid antagonist naloxone (NLX) switched off the effect of substance E (Fig. 3.6). Fig. (3.7) summarizes the effects of investigated gamma-pyridone derivatives. Both substances E and F decrease Z_{eff} , which makes it possible to predict their antinociceptive action on the organismal level.




Fig. (3.1). Structural formulae of gamma-pyridones.
 a – 5-hydroxy-1-methyl-gamma-pyridone-2-carboxylic acid (substance E), NH-form;
 b – 5-hydroxy-1-methyl-gamma-pyridone-2-carboxylic acid (substance E), OH-form;
 c – 5-hydroxy-2-hydroxymethyl-gamma-pyridone (substance F), NH-form;
 d – 5-hydroxy-2-hydroxymethyl-gamma-pyridone (substance F), OH-form.

Possible Mechanisms of Ligand-Receptor Binding of Cardiotonic Steroids

Abstract: Cardiotonic steroids are a recently discovered class of hormones synthesized in the adrenal cortex and hypothalamus and circulating in the blood. It is well known that the target molecule for these agents is Na^+, K^+ -ATPase. A direct consequence of the proposed mechanism of $\text{Na}_v1.8$ channels modulation in Chapter 1 is the prediction of a special signaling function of the sodium pump. In other words, Na^+, K^+ -ATPase should be involved in the processing of nociceptive information. The data presented in the current chapter support this idea. According to our findings, ouabain as a newly recognized hormone plays the role of endogenous analgesic at subnanomolar concentrations. Its target site is located directly on Na^+, K^+ -ATPase and it recognizes ouabain, only in the form of its calcium chelate complex. The most significant result discussed in this chapter is explanation of the dual effect of ouabain: two distinct attacking molecules (ouabain and its calcium chelate complex) bind to two distinct sites of Na^+, K^+ -ATPase, thus modulating two distinct functions of the enzyme: pumping and non-pumping (signal-transducing). Another newly recognized hormone, marinobufagenin, also exhibits analgesic effect at low concentrations but it is of principally different nature. This molecule lacks the ability to form marinobufagenin- Ca^{2+} chelate complex in 1:1 stoichiometry which could activate the signal-transducing function of Na^+, K^+ -ATPase upon binding to the enzyme. The decrease of Z_{eff} of $\text{Na}_v1.8$ channel activation gating device induced by application of marinobufagenin at nanomolar concentrations results from activation of the “modulated receptor” mechanism, *i.e.*, this molecule binds directly to the aminoacid sequence of the channel without involvement of Ca^{2+} .

Keywords: Ca^{2+} chelate complex, Limiting slope procedure, Marinobufagenin, $\text{Na}_v1.8$ channels, Na^+, K^+ -ATPase, Nociception, Ouabagenin, Ouabain, Patch-clamp method, Quantum-chemical calculations.

Endogenous cardiotonic steroids have various physiological functions. In particular, it was demonstrated that abnormal concentrations of these agents [1] could evoke different pathological states: congestive heart failure, cardiac arrhythmias [2, 3], hypertension [4], cancer [5], and depressive disorders [6, 7]. An increase of concentration of cardiotonic steroids was detected in the blood and subcutaneous water upon stress, lassitude, inflammatory processes in the

organism [8], pregnancy [9], and as a result of nephrectomy [10]. Endogenous cardiotoxic steroids also influence cell growth and proliferation [11 - 13]. Ouabain exhibits anti-apoptosis action on endothelial cells [14]. Bufadienolides may induce apoptosis in human leukemia cells [15] and they also display antiproliferative activity and immunosuppressive activity upon action on T cells [16].

PATCH-CLAMP INVESTIGATION OF CARDIOTOXIC STEROIDS

A direct consequence of our working hypothesis (Fig. 1.17) is the prediction of a new mechanism of action of cardiotoxic steroids, which should play an important role in nociception. When these agents activate the transducing function of Na^+, K^+ -ATPase, they might produce an analgesic effect. In our opinion, the most interesting objects to study are endogenous substances, such as ouabain and marinobufagenin. Obviously, these agents can exert their analgesic properties only in vanishingly small “endogenous” concentrations, since it is known that high concentrations of cardiotoxic steroids are extremely toxic. Endogenous ouabain was found in blood plasma in subnanomolar concentrations [17 - 19]. The designation “ouabain- Ca^{2+} ” is used further to distinguish low (endogenous) concentrations of ouabain from its high concentrations, as in physiologically adequate conditions endogenous ouabain should exist in the form of calcium chelate complex (see below). Fig. (4.1) illustrates $\text{Na}_v1.8$ currents in the control experiment and after extracellular application of ouabain- Ca^{2+} at 1 nM. It is clearly seen that the amplitude values of the currents are decreased (Fig. 4.1.a). The peak current-voltage curve shifts in the depolarizing direction (Fig. 4.1.b) and the left branch of this function becomes steeper at negative E after ouabain- Ca^{2+} has been applied, which results in a very pronounced decrease in Z_{eff} (Fig. 4.2.a) due to activation of the transducer-coupled membrane mechanism described in Chapter 1 (Fig. 1.17). Indeed, a nonspecific opioid antagonist naltrexone (NTX) does not switch off the effect of ouabain- Ca^{2+} (Fig. 4.2.b). These findings indicate that ouabain- Ca^{2+} can be compared to cocaine or morphine in efficiency of $\text{Na}_v1.8$ channel modulation. It switches on the three background mechanisms discussed in Chapters 1-3 that should lead to pain relief: reduces the channels density, positively shifts $\text{Na}_v1.8$ channel activation gating process and, most importantly, markedly decreases Z_{eff} . The latter process is of dose-dependent nature, showing monotonic transducer-coupled ligand-receptor binding of ouabain- Ca^{2+} in subnanomolar and nanomolar concentration range from 100 pM to 10 nM (Fig. 4.3). This binding process is characterized by $K_d = 7$ nM: extremely ouabain-sensitive branch of the dose-dependence curve reflects modulation of the signal-transducing function of Na^+, K^+ -ATPase at the membrane level. As it was mentioned above, ouabain concentrations detected in human blood plasma are of the same order of magnitude (close to K_d). Thus, according to

our results, neuronal Na^+, K^+ -ATPase as a signal transducer should be under effective control of endogenous ouabain. On the contrary, the right branch of Z_{eff} dependence on ouabain concentration is governed by a radically different background mechanism. An increase of ouabain concentration leads to inhibition of the pumping function of Na^+, K^+ -ATPase. The second process can also be approximated by the Hill equation, the K_d value in this case being much higher (0.1 mM) (Fig. 4.3). This fact leads to raising a very important question. How can one and the same enzyme (Na^+, K^+ -ATPase) distinguish between its pumping and non-pumping functions modulated by one and the same molecule (ouabain)? The answer is partly given above: endogenous ouabain exists in the form of calcium chelate complex due to the presence of free calcium in small amounts in physiological medium. An increase of ouabain concentration, given that calcium concentration remains the same, results in an important effect: “free” ouabain binds to a completely different site of Na^+, K^+ -ATPase. This fact will be explained below on the basis of our quantum-chemical calculations. Here it is worth noting that experimental evaluation of ouabain K_d carried out by different methods never led to unequivocal results, which could be in part accounted for by the heterogeneity of Na^+, K^+ -ATPase isoforms. Four isoforms of its α subunit are known to exist, and they are expressed in a cell type-specific manner in higher vertebrates. Adult rat kidney and liver cells express the $\alpha 1$ isoform; glial and skeletal muscle, both $\alpha 1$ and $\alpha 2$; sperm cells, both $\alpha 1$ and $\alpha 4$. Unlike most other cells, neurons may express $\alpha 1$, $\alpha 2$, $\alpha 3$, or any combination of these isoforms. With rare exceptions, the $\alpha 3$ isoform of Na^+, K^+ -ATPase is detected in neurons of adult vertebrates only [20]. Therefore it is not surprising that quantitative data concerning the mechanisms of binding of cardiotonic steroids to Na^+, K^+ -ATPase scatter significantly. The K_d values describing these processes vary with isoform type and they are different in rodents and humans. Human $\alpha 1$, $\alpha 2$, $\alpha 3$, and $\alpha 4$ isoforms have K_d in the range of 10^{-9} to 10^{-8} M [21 - 23]. One of these isoforms ($\alpha 1$) is ouabain-insensitive in rodents and has a very high K_d value of about 10^{-6} M [24, 25]. Furthermore, binding of cardiotonic steroids to the α subunit of Na^+, K^+ -ATPase is affected by the particular β subunit associated with it [26]. Taking into account the three α subunits ($\alpha 4$ appears to be present specifically in spermatozoa), the three β subunits and the seven FXYD subunits that have been shown to associate with Na^+, K^+ -ATPase, there are potentially 63 different receptor complexes with which cardiotonic steroids can interact [27].

Our patch-clamp data indicate that there are at least two different ouabain binding sites in Na^+, K^+ -ATPase (Fig. 4.3). Investigations of ouabain-sensitive current of Na^+, K^+ -ATPase in small neurons from adult rat dorsal root ganglia also demonstrated the existence of two ouabain binding sites, which were suggested to be located on two functionally distinct Na^+, K^+ -ATPase isozymes, $\alpha 1\beta 1$ and $\alpha 3\beta 1$, with ouabain dissociation constants of 0.2 and 140.1 μM , respectively [28].

Concluding Remarks

Abstract: Molecular mechanisms of the nociceptive information control in primary sensory neuron are described based on our investigation of the membrane signaling cascade (opioid-like receptor \rightarrow Na^+, K^+ -ATPase \rightarrow $\text{Na}_v1.8$ channel). Summarizing the data presented in this volume it is possible to conclude that modulation of $\text{Na}_v1.8$ channels responsible for the coding of noxious signals can be carried out due to two novel targeting mechanisms. The first of these is the activation of opioid-like receptors; the second is the activation of the Na^+, K^+ -ATPase signal-transducing function. Development of a novel class of analgesics that trigger these mechanisms should lead in the near future to successful solution of the problem of chronic pain relief.

Keywords: Analgesic, Modulated receptor, $\text{Na}_v1.8$ channels, Na^+, K^+ -ATPase, nociception, Opioid-like receptor, Signal transducer.

It is known that pain is unpleasant but necessary. It signals of danger, preventing us from harming ourselves, and alerts on possible damage to our bodies. Too much pain is crippling and can make everyday living an agony. That is why pain and suicide are related. Even “good” pain can turn bad, when the pain caused by an injury persists after the damage has healed. Chronic pain dramatically reduces the quality of life for millions of people. There is no doubt that any steps to develop potent and safe analgesics are of major importance. Unfortunately, no analgesics in the arsenal of practical medicine satisfy these two criteria at the same time. However, there is always hope that other opportunities to fight pain are hidden within the human body. Even the smallest practical result in finding them is very important, because endogenous mechanisms of pain relief should have no negative side effects. In our opinion, to elucidate them it is necessary to link physiology, which is the basis of medical science, with calculational chemistry that makes it possible to describe physiological events on the detailed molecular level.

The basic physiological principles should be applied to analyze the fundamental mechanisms of nociception. Ivan Pavlov was the first who revealed a strong coupling between internal inhibition processes and antagonistic nervous process of excitation [1]. Intensity of sensory signals in the peripheral nervous system is

simply coded by frequency of nerve impulses. This principle discovered by Edgar Adrian [2] is widely used by us in this book. We also rely on the assumption of Vernon Mountcastle, who formulated it as the linear operator principle [3, 4]. We take this principle into consideration when we quantitatively describe the processes of receptor- or transducer-coupled modulation of Na_v1.8 channels. In other words, we postulate that the process of ligand-receptor binding that occurs in neighboring protein molecule linearly (or monotonically) influences the effective charge value of Na_v1.8 channels activation gating system.

We believe that the novel mechanism of Na_v1.8 channels modulation in nociceptive neuron (Fig. 1.7) will open a new approach to solve the problem of chronic pain. Fig. (1.7) indicates the presence of three separate molecular targets. Each of them can interact with its “own” agonists and antagonists, some of which should be endogenous. It can be thus argued that the physiological effects of these interactions should result in the control of nociceptive signals. In accordance with our approach, antinociceptive response of sensory neuron can be obtained through activation of three different molecular mechanisms triggered by three different targets: opioid-like receptor, Na⁺,K⁺-ATPase as a signal transducer, and Na_v1.8 channel.

OPIOID-LIKE RECEPTOR-COUPLED MECHANISM OF NA_v1.8 CHANNELS MODULATION

Several unexpected manifestations of morphine action were presented in Chapter 1. We propose a completely new additional explanation of powerful analgesic effect produced by this substance. It is assumed that the opioid-like receptor-coupled mechanism is also responsible for the analgesic effect of morphine. Of course, the agent runs the well-studied opioidergic system, activation of which leads to pain relief. One terrible disadvantage property intrinsic to opioid receptor agonists, however, does not allow morphine to become an ideal analgesic. This disadvantage is the appearance of multiple negative side effects as a result of its systematic application. It is tempting to speculate that the cause of the adverse side effects of the agent at the molecular level is its ability to activate G proteins coupled to classic opioid receptors. We have found a fundamentally different mechanism of morphine action, the role of signal transducer in which is performed by Na⁺,K⁺-ATPase of nociceptive neuron [5]. Now it becomes clear that the analgesic effect of morphine is of dual nature: it activates both classic opioid receptors and opioid-like receptors physiologically described in the present book. Our results suggest that a selective agonist of novel opioid-like receptors will be free of negative side effects, since in this case the transducing function would be performed by Na⁺,K⁺-ATPase and not by G proteins. As it was shown in Chapters 1-3, activation of the Na⁺,K⁺-ATPase transducing function is a marker of

involvement of opioid-like receptors in modulation of $\text{Na}_v1.8$ channels. Identification of the selective agonist of opioid-like receptors which differs essentially from morphine both structurally and physiologically is the important result of our work. This agent is comenic acid, which, unlike morphine, binds selectively only to opioid-like receptors, thus resulting in modulation of $\text{Na}_v1.8$ channels responsible for coding of nociceptive signals.

Combined application of the patch-clamp method and quantum-chemical calculations made it possible to clarify the difference between morphine and comenic acid in their receptor-coupled ability to modulate $\text{Na}_v1.8$ channels. The latter substance, being of a significantly smaller molecular volume than morphine, specifically activates only opioid-like receptors due to its remarkable property: it can chelate calcium ions from the surrounding physiological medium. Our study on the effects of gamma-pyrone and gamma-pyridone derivatives presented in Chapters 2 and 3 allows to describe the probable characteristics of opioid-like receptor binding pocket and get an insight on molecular structure of the endogenous agonist of these receptors, which is not yet identified.

Four of six studied molecules (substances A, B, E, and F) displayed the ability to modulate $\text{Na}_v1.8$ channels, while the other two (substances C and D) were inactive. Our results made it possible to establish that the active substances should bind to the opioid-like receptor being in the form of calcium salt of calcium chelate complex and to consequently formulate the structural criteria determining the possibility for formation of ligand-receptor complexes between gamma-pyridones or gamma-pyrones and the opioid-like receptor: (1) in position 5 of the heterocycle should be present a hydroxyl or methoxy group which is capable, in combination with the carbonyl group in position 4, to chelate Ca^{2+} cation; (2) the second Ca^{2+} cation serves as the counterion at the deprotonated carboxyl or hydroxymethyl group in position 2 of the heterocycle; (3) intercationic distance $r(\text{Ca}^{2+}\cdots\text{Ca}^{2+})$ may range from 9.4 to 10.0 Å; and (4) Ca^{2+} cations should occupy specific positions with respect to the heterocycle. The major contribution to the energy of ligand-receptor binding of gamma-pyrones and gamma-pyridones is provided by strong ion-ionic interactions between bound calcium cations of the ligand and negatively charged aspartate residues of the opioid-like receptor. It is also found that the nature of the ring heteroatom may influence the ability of ligands to bind to the opioid-like receptor. Substance F, a structural gamma-pyridone analog of inactive gamma-pyrone D, exhibits $\text{Na}_v1.8$ channel-modulating effect due to the presence of intramolecular hydrogen bond between the heterocycle nitrogen atom and the oxygen atom of the hydroxymethyl group in position 2 of the pyridone ring, which fixates this substituent in the conformation appropriate for ligand-receptor binding. Several observations are made regarding the structure of opioid-like receptor binding pocket: it is, most

SUBJECT INDEX

A

Ability 3, 39, 62, 70, 72, 82, 92, 96, 97, 104, 121, 122, 127, 138, 177, 184, 185, 187, 193
 receptor-coupled 185
 Absolute temperature 16, 17
 Absolute values 17, 73, 77, 81, 84, 89, 113, 115, 119, 148, 156, 166
 Acids 66, 67, 70, 71, 72, 97, 98, 105, 107
 5-methoxy-gamma-pyrone-2-carboxylic 66, 67, 71, 72
 chelidonic 69, 70, 71, 72
 conjugate 105
 oxylic 97, 98, 107
 Aconitine 12, 13
 Action 14, 137, 176, 188, 191
 mechanisms of 14, 137, 188, 191
 ouabagenin/marinobufagenin 176
 Action potential (AP) 3, 5, 6, 7, 9, 10, 28, 190, 191, 192
 Activation function, steady-state 33, 35, 36
 Activation gate 12, 18, 21
 Activation gating device 15, 17, 28, 174, 175
 of NaV1 17, 174, 175
 Activation process 6, 9, 13, 14, 18, 33, 35, 36, 70, 122, 191, 192
 Activity 8, 13, 70, 122, 192
 impulse 6, 33, 35, 36
 receptor population 9
 Afferent fiber innervating feline
 mechanoreceptors 3
 Alkaloids 12, 13
 Almers 3, 17, 18, 19, 21, 22, 23, 24, 27, 32, 40, 41, 63, 65, 68, 97, 100, 102, 131
 Almers' method 22, 32, 40, 41, 44, 96
 Almers' procedure 20, 21
 Amplitude values 41, 63, 66, 97, 98, 128, 132, 137
 Anaesthesia 190
 local 190
 Analgesic effect 127, 128, 184, 186
 Analgesic effect of morphine 184
 Analog-impulse transformation, process of 9
 Analysis of ouabain steric structure 149

Anesthetics, local 14
 Angles, bond and torsion 107, 108, 110, 142, 145, 150, 161, 168, 172
 Antinociceptive effect of ouabain 188
 Application, combined 63, 103, 131, 185, 186
 Application of comenic acid 63, 64, 65, 66, 69, 98, 186, 188
 Application of ouabain-Ca²⁺ 130, 131
 Atomic charges in calcium salts of calcium
 chelate complexes 86, 117
 Attacking molecules 26, 127, 178
 distinct 127, 178
 endogenous 26

B

Batrachotoxin 12, 13
 Binding conformation 70
 Boltzmann constant 16, 17
 Boltzmann principle 16, 17, 19, 23, 27
 Bond angles, endocyclic 155, 165
 Bond angle values 84, 90, 111, 113, 165, 167
 Bonds 73, 75, 77, 81, 83, 84, 90, 107, 109, 110, 111, 113, 115, 117, 119, 120, 146, 147, 148, 155, 156, 157, 158, 159, 165, 166, 167, 171, 173, 174, 185, 188, 191
 intramolecular hydrogen 148, 158, 167
 cations form ion-ionic 119
 coordination 158, 191
 coordination Ca-O 155, 165
 endocyclic 110, 155, 165
 intramolecular hydrogen 73, 90, 110, 147, 185
 ion-ionic 90, 120, 188

C

Ca²⁺ cations 88, 120, 122, 185
 Ca²⁺ chelate complex 62, 72, 96, 127, 137, 149, 150, 157, 159, 160, 161, 167, 168, 175, 176
 Ca²⁺ chelation 71, 88, 90, 119, 120, 149, 150, 155, 156, 157, 160, 165, 166, 167, 176
 Ca²⁺ forms intermolecular ionic bonds 160

- Calcium 72, 82, 84, 96, 110, 113, 168
 - chelate 96
- Calcium atom 83, 84, 121
- Calcium channels 10, 27, 40
- Calcium chelate complexes 82, 85, 86, 89, 90, 91, 111, 117, 120
- Calcium chelates 72, 83, 85, 88, 89, 91, 105, 106, 107, 110, 113, 117, 119, 120, 121, 122, 127, 128, 129, 130, 177, 178, 185
 - salt of 72, 91
 - salts of 85, 91
- Calcium chelation 84, 89, 96, 105, 113
- Calcium chelation process 96, 105
- Calcium complexes 84, 90, 117, 121
- Calcium ions 96, 122, 187, 188
- Calcium salt of calcium chelate 107, 120, 121, 122, 185
- Calcium salts 72, 77, 79, 81, 84, 86, 88, 89, 90, 105, 115, 117, 119, 120, 122
 - energies of formation of 119, 120
- Calcium salts of molecules 115, 119
- Carbon atoms 156, 166
- Carbonyl groups 13, 70, 82, 122, 185, 193
- Carboxyl groups 70, 73, 75, 77, 81, 84, 90, 106, 113, 115, 117, 120
- Cardiac myocytes 137
- Cardiotonic steroids 127, 128, 129, 134, 138, 140, 159, 175, 176, 191
 - binding of 129
 - endogenous 127, 128, 134, 191
- Channel-modulating activity of gamma-pyridones 123
- Channels 3, 9, 10, 11, 12, 13, 14, 15, 16, 17, 20, 21, 23, 24, 26, 27, 28, 40, 46, 127, 135, 175, 177, 189, 190, 191, 192
 - chimeric 21, 23
 - closed 16, 17
- Channels density 63, 97, 128
- Chelates, ouabagenin–Ca²⁺ 161, 166, 167, 168
- Cinobufotalin 170, 171, 173
- Clinical application of ouabain 187
- Closed states 20, 23, 24
- Coding 3, 9, 11, 28, 30, 96, 191, 192
 - numerical 11, 191, 192
 - primary sensory 3, 9, 28, 30, 96
- Combined application of naloxone and morphine 44
- Combined application of quantum-chemical calculations 62, 69
- Comenic acid 33, 62, 63, 64, 65, 66, 69, 70, 71, 72, 89, 91, 97, 107, 113, 122, 128, 137, 185, 186, 188, 189
 - binding of 63, 186
 - extracellular application of 63
 - planar molecules of 91, 186
- Comenic acid and substance 69
- Comenic acid effects 64, 189
- Complexes, ouabagenin–Ca²⁺ 160, 161, 165, 166, 167, 168
- Complex formation 83, 88, 89, 110, 112, 119, 123, 157
- Conditioned reflexes 5
- Conformational reorganization 166, 168
 - chelation-induced 168
- Conformations 10, 26, 110, 121, 122, 140, 142, 145, 146, 147, 148, 149, 150, 155, 156, 157, 158, 160, 161, 165, 166, 167, 168, 170, 171, 172, 173, 174, 175, 176, 185
 - 17β-envelope 173
 - boat 168
 - chair 140, 146, 147, 150, 160, 173
 - examined 147, 150, 156, 157, 161, 165, 166, 167, 172
 - examined ouabagenin–Ca²⁺ 168
 - extended 121
 - half-chair 156, 166
 - initial ouabain 150
 - low-energy 142
 - lowest-energy C1 140
 - open 26
 - possible 121, 140, 150, 170
 - respective 146
 - selected ouabagenin–Ca²⁺ 165
 - selected ouabain–Ca²⁺ 155
 - stable 10, 150, 160
 - studied 150, 173
 - twist 140, 147, 150, 160, 168, 173
- Conserved aspartates 85, 90
- Crystal lattice 106, 142, 171, 173
- Currents 30, 36, 37, 38, 63, 66, 97, 98, 128, 132
 - stimulating 36, 37, 38
- Cutaneous mechanoreceptors 6

D

Depolarizing direction 44, 46, 63, 97, 128, 137
Device 25, 192
 molecular 192
 sodium channel inactivation 25
Dielectric constant 72, 75, 91, 105, 110, 119, 140
Domain 11, 12, 15, 25, 26
 voltage-sensor 26
Dorsal horn neurons 7
Dorsal root ganglia (DRG) 8, 129

E

Effective charge 17, 21, 22, 27, 40, 45, 46, 66, 68, 132, 174, 191
 normalized 45, 132
Effective charge of NaV1 3, 27, 40, 65, 97, 100, 102, 131
Effective charge transfer 15, 17, 19, 23, 24, 27, 28, 35, 39
Effective charge transfer control 44
Effective charge value 32, 33, 41, 46, 184
Effects of ouabagenin on NaV1 133
Effects of ouabain on NaV1 130
Electronic parameters 81, 109, 110, 122, 147, 148, 149, 157, 158, 166, 167, 168, 173
Electronic structure 75, 77, 82, 83, 84, 89, 90, 104, 110, 113, 117, 120, 140, 145, 149, 166
Elementary charges 16, 22, 23, 24, 25, 27, 44
Endocyclic torsion angles 142, 147, 148, 173
Endogenous activation of opioid receptors 39
Endogenous concentrations 128, 175, 177
 low 135, 137
Energies 3, 88, 89, 106, 119, 120, 123, 140, 150, 161, 175, 177, 188, 192
 cavitation 88, 119
Energies of solvated molecules 89
Equilibrium dissociation constant K_d 43
Excessive ouabain-induced Na^+ 187

F

Family of NaV1 41, 42
Fast sodium channels 22, 23, 25, 27, 29

Free acids 72, 73, 75, 77, 81, 82, 83, 84, 105, 107, 108, 110, 113
 molecules of 73, 107
Free ouabain 155, 156, 157, 160, 177
Free ouabain blocks 175
Free ouabain conformations 157
Functions 4, 9, 10, 11, 18, 19, 21, 22, 24, 31, 32, 33, 41, 46, 63, 97, 128, 129, 137, 138, 175, 177, 187, 192, 193
 non-pumping 129, 137, 138, 187
 pumping 129, 138, 175, 177, 187

G

Gamma-pyridone derivatives 92, 96, 97, 104, 120, 185, 193
Gamma-pyrone derivatives 62, 63, 69, 70, 71, 89, 91, 96, 104, 113, 188
 selective binding of 62, 69
Gating charges 19, 20, 23, 24, 25, 26
Gating charge transfer 24, 25, 28, 30
Gating devices 9, 10, 11, 26, 27, 28, 96, 191
Gating machinery 9, 10, 14, 17, 24, 25, 26, 28 complicated 24, 25
Geometry parameters 145, 168, 170
Gibbs energy of solvation 119
GNa 17, 37, 38
 maximum conductivity 37, 38
 sodium conductance 17

H

Heteroatom 92, 97, 104, 109, 120, 122, 185
 ring 97, 122, 185
Heterocyclic fragments 107, 115, 117
Heteroring 104, 110, 117, 121, 122
Heteroring plane 107, 108
High ouabain concentration 134, 136
Hill coefficient 44, 63
Hill equation 43, 44, 45, 129, 132
Hodgkin-Huxley model 18, 28, 30, 33
Horizontal line 35, 36
Hormone, recognized 127
Hormones 127, 191, 192
Hydrogen, intermolecular 158
Hydrogen atoms 106, 141, 147, 155, 157, 165, 169, 171, 176

Hydrogen bonding 140, 142, 148, 149, 167
 intermolecular 142
 intramolecular 140, 148, 149, 167
 Hydrogen bonds 13, 75, 77, 81, 82, 107, 110,
 113, 121, 141, 146, 147, 155, 157, 165,
 166, 167, 171
 Hydroxymethyl group 73, 108, 121, 122, 185
 Hypothesis, modulated receptor 14

I

Impulse firing 3, 9, 11, 28, 29, 34, 35, 37, 38,
 40, 46, 96, 189, 190, 191
 Inactivation gating machinery 15, 17, 19, 25
 Inactivation gating mechanisms 18
 Inactivation process 14, 15, 19, 20, 21, 24, 25
 kinetics of 20, 22, 41
 slow 23, 36, 39
 Inactivation system 18, 21
 Information 5, 19, 34, 138, 192
 chemoreceptor 34
 Information processing, nociceptive 186, 187
 Inhibition 4, 5, 14, 34, 35, 40, 46, 129, 159,
 187, 191
 internal 5
 receptor-induced 40
 Inhibitory interneurons 8
 Innoxious thermal receptors 6
 Inorganic cations 70, 72, 77, 90, 91, 104, 138
 Input-output functions 3, 4, 11
 Interaction of ouabain 187
 Interactions 8, 12, 13, 14, 15, 19, 24, 26, 43,
 85, 104, 122, 159, 177, 184, 187, 188
 drug-channel 14
 intermolecular 159
 intramolecular 122
 ligand-receptor 15, 43
 Intercationic distances 90, 91, 122, 185
 Intermolecular coupling 10, 15
 Intermolecular hydrogen bond 173, 177
 Intramolecular hydrogen bonding patterns
 141, 146, 147, 155, 157, 158, 165, 166,
 175

K

Kojic acid 62, 69, 70, 71, 72, 97, 107, 121,
 193

L

Langmuir law 14, 43, 44
 Ligand concentration 43, 44, 190
 Ligand-receptor 43, 91, 121, 123, 186
 stable 91, 186
 Ligand-receptor binding 91, 128
 energy of 91
 transducer-coupled 128
 Ligand-receptor binding mechanism 91, 115
 Ligand-receptor binding of cardiotoxic
 steroids 127
 Ligand-receptor binding process 44, 184
 Local anesthetics receptor 14
 Logarithmic voltage sensitivity function 18,
 20, 21, 24, 42

M

Marinobufagenin, application of 127, 135, 136
 Marinobufagenin conformations 170, 171, 173
 studied 171
 Marinobufagenin effects 135, 136
 Marinobufagenin molecules 171, 177
 Membrane 7, 8, 10, 11, 12, 14, 15, 16, 18, 26,
 27, 28, 30, 31, 32, 33, 34, 177, 191
 excitable 7, 33, 34, 191
 sensory neuron 17, 28, 30, 177
 Membrane ion channels 9, 10
 Membrane receptors 3, 14, 26, 27, 190, 192,
 193
 Methoxy group 70, 73, 75, 82, 88, 90, 120,
 122, 185
 Michaelis-Menten theory 43
 Mobility, conformational 149
 Modalities 3, 4, 5, 35, 192
 sensory 3, 192

- Modulated receptor 183
 Modulated receptor hypothesis accounting 14
 Modulate histamine H3 receptors 62
 Modulate NaV1.8 channels 185
 Modulation 9, 10, 11, 15, 17, 27, 30, 35, 96, 122, 128, 159, 176, 186, 188, 189, 191
 intermolecular 11
 receptor-coupled 96, 122, 189
 Modulation of NaV1 17, 43, 46, 134, 136, 177, 183, 185, 187, 188
 transducer-coupled mechanism of 134, 136, 177
 Molecular dynamic simulations 12
 Molecular dynamics resolution 139
 Molecular forms 15, 72, 104, 105, 120, 123, 138, 175
 distinct 138, 175
 examined 120
 possible 105, 107
 Molecular latch 15
 Molecular mechanisms of modulation of ion channels form 191
 Molecular modeling 15
 Molecular packing 142
 Molecular sieve 12
 Molecular structure 9, 47, 77, 81, 83, 84, 90, 155, 185, 193
 Molecular targets 40, 43, 46, 184
 Molecules 10, 12, 24, 27, 28, 46, 62, 68, 70, 73, 75, 77, 81, 82, 83, 84, 85, 88, 89, 90, 91, 92, 96, 97, 104, 105, 106, 107, 108, 109, 110, 112, 113, 115, 117, 119, 120, 121, 123, 127, 129, 138, 139, 140, 142, 145, 149, 159, 160, 170, 173, 175, 177, 184, 185, 186, 188, 190, 191, 192, 193
 anion 75
 atoms in 73, 110
 attacking ouabain-Ca²⁺ 160
 carboxyl group of 107, 113
 cell adhesion 12, 192
 chelate 88
 coupled protein 28
 extracellular 192
 free 149
 free acid 88
 glycoside 159
 hypothetical 186
 isolated 73, 81, 84, 105, 113
 key 10
 lactone 145
 large 140
 ligand 90, 120, 190
 neighboring 12
 neighboring protein 24, 184
 planar 91, 186
 protein 10
 signaling 193
 steroid 149
 studied 88, 89, 104, 185
 surrounding water 12
 target 127
 transducer 27
 undiscovered endogenous 186
 voltage-gated ion channel 10
 M-opioid receptors 39, 40, 70, 90, 91, 92
 classic 40
 well-studied 39
 Morphine 39, 40, 41, 43, 44, 46, 47, 62, 63, 91, 98, 128, 137, 184, 185, 186, 187, 192, 193
 addition of 41, 44
 Morphine action 40, 46, 184, 186
 Morphine application 41, 46
 combined 46
 Morphine effects 40, 42, 44, 91
 Morphine molecule 92, 186
 Morphine molecule occupies 91
 Mulliken atomic charges 107, 145, 156, 166
 Mutual orientation of rings 148, 156, 166
 Myelinated nonnociceptive afferents 8
- N**
- Na⁺, K⁺-ATPase binding sites 187
 Na⁺, K⁺-ATPase complexes 149
 Na⁺, K⁺-ATPase control 178
 Na⁺, K⁺-ATPase-coupled 188
 Na⁺, K⁺-ATPase enzyme 192
 Na⁺, K⁺-ATPase function 160
 Na⁺, K⁺-ATPase inhibition 187
 Na⁺, K⁺-ATPase isoforms 129, 187
 Na⁺, K⁺-ATPase isozymes 129
 Na⁺, K⁺-ATPase molecule 138, 186
 Na⁺, K⁺-ATPase pumping activity 138

- Na⁺, K⁺-ATPase pumping function 138, 159, 176, 187
 Na⁺, K⁺-ATPase scatter 129
 Na⁺, K⁺-ATPase signal-transducing function 137, 183, 188
 Na⁺, K⁺-ATPase site 177
 Na⁺, K⁺-ATPase Sodium-potassium 192
 Na⁺, K⁺-ATPase transducing function 184
 Na⁺, K⁺-ATPase transducing site 177
 Naloxone 44, 46, 90, 192, 193
 nonspecific opioid receptor blocker 44
 Naloxone and ouabain nullify 46
 Naltrexone 66, 68, 192, 193
 NaV1.8 channel activation gating device 3, 27, 44, 97, 127, 177
 NaV1.8 channel activation gating system 21, 28, 40, 46, 66, 98
 NaV1.8 channel density 38, 39
 NaV1.8 channel-modulating activity 92, 186
 NaV1.8 channel-modulating agents 33
 NaV1.8 channel-modulating effect 170, 185
 NaV1.8 channel modulation 63, 128, 187
 NaV1.8 channels activation gating device 65, 100, 102, 131
 NaV1.8 channels activation gating process 98
 NaV1.8 currents 41, 42, 63, 97, 128, 135, 137
 Negative side effects 43, 46, 47, 63, 183, 184
 Nerve fibers 3, 4, 6, 190
 Nerve impulses 3, 5, 6, 10, 11, 24, 29, 34, 35, 190
 trains of 5, 24, 34, 35
 Nervous system 3, 4, 190, 192
 Neurons 7, 8, 9, 28, 39, 129
 projection 8
 spinal cord 7, 8
 Neutral molecule 105
 NH-tautomers 105, 106
 Nociception 3, 4, 9, 28, 62, 63, 96, 123, 127, 128, 177, 183, 189, 191, 192
 mechanisms of 3, 9, 189
 Nociception orphanin FQ peptide receptor 39
 Nociceptive afferents 6, 7
 Nociceptive membrane 9, 10, 28, 30, 35, 37
 Nociceptive membrane excitation control
 mechanisms 28
 Nociceptive membrane impulse firing 3, 28, 33
 Nociceptive neuron 28, 33, 34, 36, 39, 137, 184, 191
 Nociceptive neuron excitability 33
 Nociceptive neuron membrane 9, 17, 19, 28, 34, 41, 137
 excitability of 17, 19
 Nociceptive signals 4, 5, 6, 7, 8, 9, 11, 30, 35, 37, 38, 185, 186, 187, 188, 191, 192
 coding of 9, 30, 185, 191, 192
 Nociceptive system 7, 9, 10, 11, 30, 134, 137, 186, 187, 191, 192
 Nociceptors 5, 6, 7, 8, 9, 192
 unmyelinated 7, 8
 Normalized peak conductance 65, 100, 102
 Novel analgesics 3, 35, 189, 191, 192
- O**
- Opioid receptor agonists 184
 Opioid receptor families 39
 Opioid receptors 39, 40, 44, 69, 70, 184, 187, 192
 classic 184
 Opium alkaloids 192
 Ouabagenin 127, 132, 133, 134, 135, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 160, 165, 166, 167, 168, 169, 170, 174, 175, 176, 177
 application of 132, 133, 134, 177
 free 165, 166
 Ouabagenin action 175
 Ouabagenin–Ca²⁺ 166, 168
 Ouabagenin–Ca²⁺ Chelate Complexes 160
 Ouabagenin–Ca²⁺ geometry parameters 160
 Ouabagenin–Ca²⁺ spatial structures 176
 Ouabagenin calcium chelates 168
 Ouabagenin conformations 140, 141, 145, 160
 possible 160
 Ouabagenin conformers 142
 Ouabagenin crystallizes 140
 Ouabagenin effect 134, 175
 Ouabagenin molecule changes 149
 Ouabagenin molecules 140, 146, 147, 149, 176
 Ouabagenin–Ca²⁺ 169
 Ouabagenin–Ca²⁺ 169

- Ouabain 46, 63, 66, 68, 127, 128, 129, 130, 132, 134, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 155, 156, 158, 159, 160, 168, 170, 174, 175, 176, 177, 178, 186, 187, 188, 191, 193
ability of 138, 175, 188
application of 130, 175
cardenolides 170
combined application of 66, 68, 132, 134, 135, 136, 175
conformation C2 of 141, 145
conformation of 142, 145
dual effect of 127, 178, 187
electronic structure of 156, 158
endogenous 128, 129, 137, 187, 188
examined 145
isolated 140
preliminary application of 175
stable 149
ternary 177
- Ouabain and ouabagenin 138, 139, 140, 142, 145, 146, 147, 149, 168, 175, 176
electronic structure of 140, 149
examined conformations of 142, 147
fragments of 145, 149
- Ouabain and ouabagenin conformations 140, 146
- Ouabain and ouabagenin molecules 146, 147, 149, 176
- Ouabain binding 137, 149, 159, 160, 176, 187
selective 149
- Ouabain binding sites 129, 138
- Ouabain–Ca²⁺, ternary 160
- Ouabain–Ca²⁺ 128, 130, 131, 149, 168, 176
- Ouabain–Ca²⁺ binding 132
- Ouabain–Ca²⁺ chelate complexes 149
- Ouabain–Ca²⁺ chelates 137, 150, 157, 158, 159, 160, 175
- Ouabain–Ca²⁺ complexes 150, 156, 157, 168
- Ouabain–Ca²⁺ conformations 149, 157
studied 157
- Ouabain–Ca²⁺ parameters 150
- Ouabain–Ca²⁺ system 150
- Ouabain calcium chelates 168, 177
- Ouabain concentrations 128, 129, 132
extracellular 132
- Ouabain control 138
- Ouabain crystal hydrate 138
- Ouabain dissociation constants 129
- Ouabain effect 176
- Ouabain molecule 132, 140, 147, 149, 150, 158
free 150, 187
- Ouabain–Na⁺ 149, 158
quasi-irreversible 149
- Ouabain-sensitive branch 128
- Ouabain steric structure 149
- Oxygen atoms 70, 77, 82, 92, 97, 104, 105, 107, 147, 148, 149, 150, 155, 156, 157, 158, 160, 165, 166, 167, 173, 176, 177, 185, 193
carbonyl 105
carboxyl 77
chelating 158
ring 70
- Oxygen atoms binding Ca²⁺
- ## P
- Pain 4, 5, 6, 7, 8, 10, 35, 39, 62, 183, 184, 190, 192
chronic 8, 10, 35, 183, 184
- Pain perception 5, 7, 8
- Pain relief 9, 17, 28, 37, 46, 128, 177, 183, 184, 189
- Pain sensation 4, 6, 7, 8, 36, 38, 39, 190
- Pain sensation threshold 36, 37
- Parameters 81, 110, 122, 148, 149, 157, 167, 191
geometry and electronic 81, 110, 122, 148, 149, 157, 167
molecular 191
- Physiological conditions ouabain 187
- Polarizable continuum model (PCM) 72, 105, 108, 121
- Pyridone 97, 185, 193
- ## Q
- Quantum-chemical calculations 62, 69, 89, 90, 91, 96, 120, 122, 127, 129, 138, 146, 168, 170, 185, 187

R

Receptor activation 14
 Receptor binding pocket 70, 72, 85, 90, 91, 92, 96, 121, 122, 185, 186
 Receptor binding pocket milieu 105
 Receptor binding site 119
 Receptor complexes 129
 Receptor concentration 43
 Receptor-coupled membrane mechanism 63, 98
 Receptor mechanism, modulated 127, 135, 137, 177, 188, 189
 Receptor molecule 91
 Receptor population 9
 Receptor properties 70
 Receptor protein 44
 Receptor-regulated ionic channels 26
 Receptors 5, 9, 90
 activated 9
 opioid-like 90
 primary 5
 Recognition, receptor-coupled molecular 188
 Residues 11, 12, 15, 70
 charged 15, 70
 charged aminoacid 11, 12
 Rhamnose 142, 148, 149, 157
 Rhamnosyl residue 140, 146, 147, 148, 149, 169, 177
 RHF geometry optimization 73, 75, 77, 79, 82, 85, 86, 111, 113, 115, 117
 Rigidity, conformational 139
 Rings, rhamnosyl 145, 158

S

Salt formation 88, 89, 115, 119, 120
 Salt molecule minus 88
 Salt molecules 81, 115
 electroneutral 115
 Salts 72, 77, 81, 84, 88, 89, 90, 91, 117, 119, 122
 energies of 89, 119
 energies of formation of 88, 89
 energies of formation of sodium and calcium 89, 90
 Sensory receptors 5, 190

 specialized 5
 Sequence 10, 11, 14, 15, 16, 127, 177
 aminoacid 10, 11, 14, 16, 127, 177
 Shaker potassium channels 26, 27
 Side effects, adverse 184, 186, 188, 189
 Signal-transducing 127, 178, 192, 193
 Signal-transducing function 127, 128, 138, 175, 177, 187, 188
 Signal transduction 27, 39, 47, 175, 188, 193
 opioid receptor 39
 Skin receptors, adapting 6
 Sodium and calcium salts 72, 77, 81, 89, 90
 Sodium channel activation 12
 Sodium channel inactivation 15
 Sodium channel protein 15
 Sodium channels 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 24, 27, 28, 29, 31, 190
 classical 11, 16
 gating machinery of 10, 14, 24
 open 16, 17
 slow 13, 27, 28, 31
 voltage-dependent 16, 24, 190
 Sodium conductance 16
 Sodium currents 19, 20, 21, 22, 23, 29, 41, 64, 67, 99, 101, 130, 133, 135
 family of 19, 21, 22, 23
 slow 20, 21
 Sodium pump inhibition 177
 Solvated molecules 88, 89
 Solvation effects 72, 75, 89, 110
 Solvation of molecules 90
 Space, conformational 139
 Spike frequency adaptation 9, 10, 11, 23, 190, 191
 Spinal cord 8
 Stereochemical formulae of ouabain 139
 Steric structures 72, 91, 107, 122, 145, 150, 155, 165, 169, 170, 175, 176
 Steric structures of gamma-pyrone 72
 Steric structures of ouabain and ouabagenin 139
 Steroid core 139, 140, 142, 145, 146, 148, 149, 150, 156, 158, 160, 167, 168, 170, 173
 Stimulus force 6
 Stimulus intensity 3
 Stimulus strength 35, 39
 Stoichiometry, acid-Ca²⁺ 77

Structural formulae of gamma-pyridones 98
Structural formulae of substances 69
Structural gamma-pyridone analog 185
Superposition of steric structures of ouabain–
Ca²⁺ 169
Supplementary geometry optimization of
solvated molecules 89

T

Theory, gate control 8
Torsion angles 73, 83, 107, 108, 109, 110,
111, 112, 113, 114, 115, 116, 117, 118,
121, 142, 145, 147, 148, 150, 152, 155,
161, 162, 166, 168, 171, 172, 173, 174
absolute values of 155
absolute values of endocyclic 142, 173
Torsion angle values 140, 142, 165, 166
Transfers, gating particle 24, 25
Transition, inducing conformational 16
Transmembrane 15, 16

Triggering receptor structures 193

V

Varied dielectric constant 73, 75, 77, 79, 82,
85, 86, 111, 113, 115, 117
Vasodilatation 7
Veratridine 12, 13
Voltage-clamp data, experimental 23, 24
Voltage dependencies 23, 31, 32, 63, 97
Voltage sensitivity 15, 17, 40, 44, 62, 68
Voltage sensor 10, 15, 16, 17, 25, 26

Z

Zeff dependence on morphine concentration
44
Zeff evaluation 18, 39, 42, 65, 68, 100, 102,
131
Zeff value 18, 21, 22, 23, 32, 41, 66, 132, 135

“ This volume deals with the study of molecular ligand-receptor binding mechanisms that modulate Na_v1.8 channels responsible for nociceptive signal coding. Investigations of the membrane signaling cascade (opioid-like receptor, Na⁺, K⁺-ATPase as a signal transducer, slow sodium channel) reported in this book open new approaches for the development of a novel class of analgesics.

*Pawan Singal, PhD, DSc, FACC
Professor and Director
Institute of Cardiovascular Sciences
St. Boniface Hospital Albrechtsen Research Centre
Canada* ”



Boris V. Krylov

Boris Krylov is Ph.D., Dr.Sci., Professor in Physiology (born 1949). He is a fellow of Alexander von Humboldt Foundation. His academic appointments include: Deputy Director 1997-2015 (Pavlov Institute of Physiology RAS); Head of the Laboratory of Physiology of Excitable Membranes since 1997 to the present. He is the author of more than 200 original publications in the field of physiology, including an article published in Nature and a monograph published in Springer, and of 7 patents, among which there are 3 USA/PCT patents. His scientific interests are focused on elucidation of molecular mechanisms of functioning of living cells.



Ilia V. Rogachevskii

Ilia Rogachevskii (born 1978) is Senior Research Scientist at the Laboratory of Physiology of Excitable Membranes of Pavlov Institute of Physiology RAS, Saint Petersburg, Russia from 2006 till the present. Ilia Rogachevskii achieved his M.Sc. degree in Inorganic Chemistry in 1999 and his Ph.D. in Computational Chemistry in 2003 (both at Saint Petersburg State University). He has been working in the field of calculational chemistry for almost 20 years and is the author of more than 80 original publications in Russian and international journals. His scientific projects involve application of quantum-chemical methods to investigation of molecular mechanisms of ligand-receptor binding.



Tatiana N. Shelykh

Tatiana Shelykh works as Research Scientist at the Laboratory of Physiology of Excitable Membranes of Pavlov Institute of Physiology of Russian Academy of Sciences, Saint Petersburg. She has over 10 years experience in physiology and neurosciences and is the author of more than 50 scientific publications in this field. Tatiana Shelykh achieved her Ph.D. in Molecular Biology (2009). Throughout recent years of her postgraduate study she has been working at the Pavlov Institute, applying the patch-clamp method to clarify the mechanisms of modulation of NaV1.8 sodium channels by cardiac glycosides and other molecules of both endogenous and exogenous origin.



Vera B. Plakhova

Vera Plakhova occupies a position of Senior Research Scientist at the Laboratory of Physiology of Excitable Membranes of Pavlov Institute of Physiology of Russian Academy of Sciences, Saint Petersburg, Russia from 1998 till the present. She achieved her M.Sc. degree in 1996 (Saint Petersburg State University), and her Ph.D. in 2000. She has participated in more than 10 international meetings, congresses, and symposia in physiology, biophysics, and neurosciences since 1996. She has published more than 100 original papers on physiology, biophysics and membrane biology. She is the author of USA/PCT patent.